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Abstract
Neuropsychological functioning turns out to be a rate-limiting factor in psychiatry. However, little is known when comparing 
neuropsychological and psychosocial functioning in inpatients with schizophrenia or severe depression in their treatment 
pathways including add-on psychoeducation or the latter combined with cognitive behavioral therapy up to 2-year follow-up. 
To evaluate this question, we investigated these variables in two randomised controlled trials including 196 patients with 
DSM-IV schizophrenia and 177 patients with major depression. Outcome measures were assessed in the hospital at pre- and 
posttreatment and following discharge until 2-year follow-up. We focused on neuropsychological and psychosocial function-
ing regarding its differences and changes over time in data of two pooled trials. There were significant time effects indicat-
ing gains in knowledge about the illness, short and medium-term memory (VLMT) and psychosocial functioning (GAF), 
however, the latter was the only variable showing a time x study/diagnosis interaction effect at 2-year follow-up, showing 
significant better outcome in depression compared to schizophrenia. Moderator analysis showed no changes in psychosocial 
and neuropsychological functioning in schizophrenia and in affective disorders due to age, duration of illness or sex. Looking 
at the rehospitalisation rates there were no significant differences between both disorders. Both groups treated with psych-
oeducation or a combination of psychoeducation and CBT improved in neuropsychological and psychosocial functioning 
as well as knowledge about the illness at 2-year follow-up, however, patients with major depression showed greater gains in 
psychosocial functioning compared to patients with schizophrenia. Possible implications of these findings were discussed.
Keywords Schizophrenia · Major depression · Neuropsychological functioning · Psychosocial functioning · 
Psychoeducation · Cognitive-behavioral therapy · Illness management · Rehospitalisation rate
Introduction
Schizophrenia and major depression create a wide range of 
personal challenges. These cover unpredictable relapses, 
difficulties with cognitive functioning and loss of social 
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support [1]. According to the World Health Organisation, 
depression will be the most important contributor to the 
global burden of disease by 2030 [2]. Prevalence of major 
depression is around 10% and of schizophrenia around 1% 
showing a much earlier onset of the illness in schizophrenia 
compared to depression [3–5].
Psychopharmacological interventions play a major role in 
the treatment of acute schizophrenia and severe depression. 
They are to reduce the severity of acute symptoms [6−7] 
and prevent relapses. However, medications have negligible 
effects on cognitive and psychosocial functioning [8]. There 
is need for additional psychosocial interventions to address 
the 20–30% of patients with schizophrenia having persis-
tent symptoms and relapses despite adherence to antipsy-
chotic medications [6–7] and the 15% of patients with major 
depression having an unremitting course [9].
Lack of insight and poor treatment adherence with psy-
chopharmacological and psychological interventions are 
characteristics of both illnesses asking for interventions to 
increase patients’ understanding of their psychiatric condi-
tion, the principles of treatment, and training of strategies to 
cope with the illness and to pursue goals. Meta-analyses over 
the last twenty years have shown that cognitive behavioral 
therapy (CBT) and psychoeducational interventions (PE) 
are effective in the treatment of schizophrenia and major 
depression [10–16].
Studies comparing neuropsychological functioning of 
schizophrenia and major mood disorders have produced 
somewhat mixed results [17–21]. Looking at neuropsy-
chological functioning in meta-analytic studies, there was 
a considerable overlap in healthy and depressed persons, 
however, fewer matching between the latter and persons with 
schizophrenia [22−25] and major depression with psychotic 
features (MDDP) [21]. Vulnerability to psychotic experi-
ences conferred a risk for cognitive deficits [23]. Assess-
ment of domain specificity within psychotic disorders, on a 
backdrop of global impairment, revealed the largest deficit in 
processing speed in schizophrenia [24] and relatively greater 
impairment in verbal memory across all groups [20]. There 
was no evidence for categorical differences between schiz-
ophrenia, schizoaffective and affective disorder, however, 
for a subgroup of patients with schizophrenia having more 
severe negative symptoms being cognitively more impaired 
than the rest [26]. Comparing inpatients with schizophre-
nia, major depression and healthy controls, showed patients 
with both disorders to be significantly impaired compared to 
healthy controls and to improve at follow-up [27]. A recent 
analysis showed effects of psychosocial interventions in 
outpatient settings on social functioning in depression and 
schizophrenia [28].
Based on these studies as well as our expertise [29−30], we 
developed two psychoeducational group programs in schizo-
phrenia and major depression that were combined with coping 
enhancement in the first and CBT in the latter to be delivered 
in inpatient treatment including a 2-year follow-up. From our 
point of view, there was little research on inpatients [31−32], 
and guidelines [33−36] voting for studies with long-term effi-
cacy needed more approval. The fact that one study focused on 
schizophrenia and one on major depression would potentially 
allow interesting comparisons of the clinical and functional 
outcomes in the two disorders. There are important advantages 
of this study based on a large sample size and each of the 
randomized controlled trials based on basic methodology that 
have been published previously. The paramount aim of this 
add-on study is therefore to develop more specific and efficient 
psychological interventions for inpatients with schizophrenia 
and depression to improve treatment adherence, to minimize 
depressive symptoms in acute episodes and to prevent relapses 
and worsening of symptoms.
To our knowledge there are no 2-year follow-up studies 
available comparing patients with schizophrenia and major 
depression in different treatment pathways. Psychoeduca-
tion [16] and cognitive-behavioral therapy [11−15] have 
gained prominence in the treatment of schizophrenia and 
major depression, however, few is known when comparing 
overall functioning starting with inpatient treatment fol-
lowing a symptom exacerbation up to 2-year outcome. We 
therefore compare the results of two randomised controlled 
trials focusing first on long-term effects of 196 inpatients 
with schizophrenia attending a group-based coping-oriented 
psychoeducational (COP) [37] or supportive program (SUP). 
Second, we focus on the long-term effects of 177 depressed 
inpatients attending an extended clinical management 
(E-CM), psychoeducational CBT group treatment (PCBT-G) 
and PCBT combined with individual sessions (PCBT-G + I) 
[38]. Psychoeducation and CBT were add-on interventions 
as all patients were treated with pharmacotherapy.
The study focuses on differences and changes in psychoe-
ducational coping-oriented group treatment (COP) in schiz-
ophrenia and the combination of psychoeducational CBT 
group treatment (PCBT-G) in major depression focusing 
on duration of illness, symptom changes, psychosocial and 
neuropsychological functioning and, rehospitalisation rates. 
We expect participants with schizophrenia to have a much 
earlier onset of the illness [3−5], to worsen over time and to 
have lower levels of neuropsychological and psychosocial 
functioning as well as worse course of the illness compared 
to depressed patients at 2-year outcome [17, 23, 25, 28].
Methods
Studies and participants
A total of 196 patients with schizophrenia [37] and 177 
with major depression [38] participated at different group 
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programs in randomised controlled trials at the Department 
of Psychiatry and Psychotherapy, University Hospital, LMU 
Munich. Inclusion criteria were: (1) 18 to 65 or 69 years old, 
(2) diagnosis of schizophrenia spectrum disorder or other 
psychotic disorder respective major depression made by 
treating psychiatrists according to DSM-IV [39], (3) post-
acute stage of the illness (i.e., remission of acute symptoms), 
(4) proficient in German, (5) sufficiently stable to participate 
in group therapy, (6) written informed consent. Exclusion 
criteria were: (1) organic brain syndrome, (2) current drug 
or alcohol dependence, (3) acute suicidality, (4) level of 
intelligence < 85. Both studies were approved by the Univer-
sity Institutional Review Board and set up in a comparable 
time-frame.
The first study compared the long-term effects of a cop-
ing-oriented psychoeducational program (COP) with an 
equally intense supportive therapy (SUP) in schizophrenia. 
We refer to interventions focusing on education, teaching 
more effective coping strategies, and cognitive restructuring 
as “coping-oriented” programs [37, 40–42] as they endeavor 
to foster more adaptive coping with schizophrenia through 
a wider variety of strategies than that  are usually employed 
by either cognitive-behavioral or the illness management 
program. Patients in CBT and in coping-oriented treatment 
were also offered psychoeducational sessions about the ill-
ness and its treatment lasting about 6 weeks in total. The 
second study compared three treatment conditions including 
extended clinical management (E-CM), psychoeducational 
cognitive behavioural group treatment (PCBT-G) or the lat-
ter in addition to individual outpatient treatment (PCBT-
G + I) in major depression. Detailed information about par-
ticipants, procedures, organization of the treatment program, 
its contents and data-analysis is provided [37−38]. There 
were group treatment guidelines available for both disor-
ders lasting for 12 sessions with two sessions per week to 
encourage direct communication between inpatients, while 
also establishing a structure for the therapists to convey 
essential information and skills. In both studies, the agenda 
of the sessions were supplemented by materials including 
flipcharts, handouts and homework assignments [40–42].
Measures
At baseline and post-treatment, 6–8 weeks later, and 1 
and 2 years following discharge from the hospital, we 
assessed clinical and sociodemographic variables by clini-
cal interviews and questionnaires at both study samples by 
trained clinical psychologists. This paper comprises both 
studies focusing on the same criteria of outcome. Psycho-
social functioning was assessed with the Global Assess-
ment Functioning Scale (GAF, DSM-IV [39, 43]) rang-
ing from poor (0) to high (100) functioning. Knowledge 
about schizophrenia or depression and its treatment were 
assessed using a modified multiple choice test [44]. There 
were comparable numbers of questions in both instruments 
with 26 respective 28 questions about diagnosis, its aeti-
ology, symptoms, and treatment strategies in schizophre-
nia and in depression, however due to a different coding 
there were only half of the credit points in the first test. 
Knowledge was defined as number of correct answers, 
with scores ranging from 0 to 60 in schizophrenia and 0 
to 114 in depression. Neuropsychological functioning was 
assessed with the German version of the Verbal Learning 
Memory Test [45] measuring verbal learning and memory. 
It includes immediate recall (reflecting concentration and 
memory), cumulative learning with exposure and practice, 
interference, long-delay recall and recognition discrimina-
bility. Subjects are instructed to recall as many words of a 
15-item list as possible, after each of five separate learning 
trials. A new list is presented once, requiring immediate or 
recall of the learning curve, interference, or after a long-
delay (20 min) free recall of the first list. Finally, a list of 
words is read to the subject, who is asked to recognize 
words from the first list (recognition discriminability). Sat-
isfaction with treatment was assessed using a 4-item ques-
tionnaire administered at the end of each treatment group 
in both studies, covering psychoeducation and practicabil-
ity of skills learned [46]. At each assessment, information 
about antipsychotic and anticholinergic medications was 
obtained, and chlorpromazine-equivalents were calculated 
[47]. Rehospitalization was determined by a combination 
of participant interview and review of medical records.
Data analysis
Baseline differences in demographic and clinical variables 
as well as in the two samples of patients with schizophre-
nia or with depression were evaluated with chi-square and 
independent t-tests. For main outcomes, we performed 
linear mixed-effects regression analyses with three (pre-
treatment, 1-year follow-up, 2-year follow-up) measure-
ments for VLMT and four measurements (pre-treatment, 
post-treatment, 1-year follow-up, 2-year follow-up) for 
GAF and knowledge, respectively. Measurements were 
considered as nested within patients, and an unstructured 
covariance structure was assumed. Time and study/diag-
nosis as well as their cross-level interaction time × study/
diagnosis were introduced as fixed factors, effects of age 
and duration of disease were controlled for by including 
these variables as covariates. On the patient level, a ran-
dom effect was included for the intercept to take individ-
ual symptomatic variation at baseline into account. Effect 
size was reported as Cohen’s d. Results were significant at 
p < 0.05. Analyses were performed using the lme4 package 
in R, version 3.5.2.
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Results
Table 1 summarizes the demographic and clinical data 
of inpatients with schizophrenia and major depression at 
pre-treatment.
This table shows the number of hospitalizations over 
the 2 years and mainly focuses on participants in COP in 
study 1 and for PCBT in study 2. Patients with schizo-
phrenia participating at the coping-oriented study (COP) 
were significantly younger compared to patients with 
depression attending the psychoeducational cognitive 
behavioral treatment group (PCBT-G). The first sample 
also had a significantly shorter duration of illness. Age 
and duration of illness were included as covariates in the 
following data analysis. There were no significant differ-
ences in sex between the two groups with 53% male in the 
first vs. 57% female in the second sample:  chi2 test: Pear-
son’s Chi-squared test with Yates’ continuity correction X2 
(1) = 2.6979, p = 0.1005. However, 71% of patients with 
schizophrenia were single compared to 39% of depressed 
patients and 61% of patients with depression had a rela-
tionship or were married (t = 11.55, p > 0.01). The pre-
treatment scores of GAF [39] and VLMT [41] in both 
samples were comparably low M = 49.48 (SD = 14.41), 
M = 49.07 (SD = 13.66) indicating symptoms at a moder-
ate level including flat affect, circumstantial speech, occa-
sional panic attacks or moderate difficulty in social and 
occupational functioning e.g., few friends, conflicts with 
peers or co-workers.
Figure 1 shows the number of hospitalizations at pre-
assessment in both samples. 45% of patients with depres-
sion versus 30% of patients with schizophrenia had their 
first episode and hospitalization (x2 = 29.29, p < 0.01), 
however, in schizophrenia there was an increasing num-
ber of hospitalizations indicating a more chronic course 
of the illness.
Table 2 shows neuropsychological and psychosocial 
functioning from pre-treatment to 2-year follow-up. The 
average knowledge  [44] about schizophrenia and its treat-
ment at pre-treatment was M = 76.54; SD = 12.45 com-
pared to M = 92.85; SD = 12.51 in depression. At 2-year 
follow-up both groups increased their knowledge with 
an average knowledge about schizophrenia and its treat-
ment with M = 85.57; SD = 12.33 compared to M = 99.48; 
SD = 11.93 in depression (p < 001). However, there was no 
significant time × study effect of knowledge. The average 
scores of the Verbal Memory Test  [45] indicating imme-
diate recall and short-term memory were comparable at 
pre-assessment in COP and PCBT with 6.43 and 6.37. At 
2-year follow-up, the average score in COP was M = 8.36 
(SD = 2.92) and in CBT-G, M = 8.21 (SD = 2.2) show-
ing significant time effects for both groups (p =  < 0.001), 
however, no time × interaction effect. Looking at the 
learning curves in medium-memory  [45], there were also 
significant time effects in schizophrenia and depression 
(p =  < 0.001) as well as a study effect (p = 0.012). The first 
group showed a broader deviation of scores than the latter. 
The GAF scores  [39] of both studies showed comparable 
mean scores in schizophrenia and in depression at pre-
treatment, however, an increasing gap during the course 
of the study at 2-year follow-up showed a significant time-
effect as well as time × treatment effect in favour of major 
depression (p =  < 0.001). There was no difference in sat-
isfaction with the treatment program in both studies as we 
adapted the treatment strategies to the given possibilities 
of the patients  [46].
We found signif icant t ime effects for GAF 
(F(1,796.47) = 683.067, p < 0.001), VLMT immediate 
recall (F(1,416.87) = 90.50, p < 0.001), VLMT learning 
curve (F(1,354.57) = 61.83, p < 0.001), and knowledge 
(F(1,799.42) = 40.37, p < 0.001), indicating group-unspe-
cific improvements over time in all outcomes. Significant 
group  effects for GAF (F(4,688.07) = 3.89, p = 0.004), 
VLMT immediate recall (F(4,488.10) = 3.71, p = 0.006), 
VLMT learning curve (F(4,420.51) = 6.867, p < 0.001), and 
knowledge (F(4,891.99) = 74.97, p < 0.001), are reflective 
of a generally higher level of functioning in the depressed 
patients as compared to the schizophrenic sample. For 
the GAF, a significant time × group interaction was found 
(F(4,791.82) = 4.47, p = 0.002), revealing group-specific dif-
ferences in trajectories between E-CM and COP, E-CM and 
SUP, PCBT-G and SUP, as well as PCBT-G + I and SUP 
(Table 2).
Data about the course of the illness in both studies are 
shown in Table 3: Flow of participants and cumulative 
rehospitalisation rates at 2-year follow-up in both studies. 
There was a higher treatment adherence in schizophrenia 
[37] (125 of 196) compared to major depression [38] (96 of 
177). Although we expected the coping-oriented treatment 
program to be superior to supportive treatment in prevent-
ing rehospitalization at 2-year follow-up period, both groups 
had comparable but relatively low rates of rehospitalization 
over this period (COP: 38, SUP: 37) [37]. These results are 
similar to other studies [48−49], such as the recently for 
the National In stitute of Mental Health sponsored Recov-
ery After Initial Schizophrenia Episode-Early Treatment 
Program (RAISE-ETP) study [48], a cluster randomized 
controlled trial involving 34 sites in which the 2-year hospi-
talization rate for participants in the specialty comprehen-
sive treatment program for first episode psychosis was 34%, 
compared to 37% for those who received usual community 
care. The psychoeducational approach in the PIP-Study 
offering information about symptoms, pharmacotherapy and 
relapse plan to patients and their relatives in distinct groups 
was 41% compared to 58% in standard treatment [49]. The 
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inclusion of relatives was mandatory in this design, and 
thus the results could reflect the effects of family psychoe-
ducation, an established practice for reducing relapses and 
hospitalizations in schizophrenia [44]. This study included 
mainly affiliated outpatients, whereas in our sample only 
15% of the patients were temporary outpatients. Compara-
ble to this study our participants were inpatients, however, 
our inclusion criteria were broader as we also included first 
episode patients (about 1/3 of the sample) and there was no 
request for study participation that relatives also attended 
psychoeducational groups. At 2-year follow up, participants 
in PCBT-G [38] had significantly lower rehospitalisation 
rates (27%) than those in E-CM (40%) (t (98.61) = 2.96; 
p ≤ 0.004; NNT = 3.8) as well as those in CBT-G + I (34%) (t 
(114.01) = 2.22; p ≤ 0.028; NNT = 4.7), whereas the rehospi-
talisation rates between PCBT-G + I and E-CM did not differ 
significantly. Table 3: Flow of participants and cumulative 
rehospitalisation rates at 2-year follow-up in both studies.
See also Supplementary data: (Supplementary Fig. 1, 
Supplementary Tables 1, 2, 3).
Discussion
Comparable to other studies including patients with MD and 
with schizophrenia, the first group was significantly older 
at illness onset, had a shorter duration of illness and was 
socially better integrated than patients with schizophrenia—
although in our sample there was no majority of women 
[3–5]. Our hypothesis about neuropsychological and psy-
chosocial functioning in schizophrenia was confirmed in 
psychosocial functioning, however, rejected in neuropsy-
chological functioning. There were no interaction effects 
in knowledge about the illness [43], in immediate recall 
and the learning curve of verbal learning [45], however, in 
global functioning [39], there were higher scores in depres-
sion compared to schizophrenia at 2-year follow-up. In our 
study pre-scores of GAF [39] were at a low-level compa-
rable in schizophrenia and in depression, however, the gap 
increased at 2-year follow-up (p =  < 0.001) showing time × 
treatment effects in favour of MD as well as main effects. 
Patients with schizophrenia were rated as having symptoms, 
transient, and expectable reactions to psychosocial stress-
ors, having only slight impairment in social, occupational 
or school functioning compared to patients with depression 
who were rated as having no or minimal symptoms, good 
functioning in all areas, interested and involved in a wide 
range of activities. Patients with depression were rated as 
socially effective, generally satisfied with life and having 
no more than everyday problems or concerns. Comparable 
to other studies psychosocial interventions for depressed 
patients [28] were effective at improving social function-
ing, however, in schizophrenia, evidence from high quality 
trials is limited.
Fig. 1  Number of hospitalisations in COP (BOT) vs number of hospitalisations in P-CBT (VOG) at pre-assessment
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Inpatients with schizophrenia performed lower than 
patients with depression at pre-assessments in some tests, 
however, better in others and at follow-up, both patient 
groups showed improved performance. The findings do 
not show greater cognitive impairment in schizophrenia 
compared to depression to be a trait marker and differen-
tiating both disorders at the basis of cognitive functioning 
seems to be less specific than expected.  [27] The only sig-
nificant study/diagnosis × time interaction is in psychoso-
cial functioning showing patients with schizophrenia to be 
more impaired at 2-year follow-up compared to patients 
with depression. In both studies the number of participants 
decreased at 2-year follow-up, however, there was a higher 
treatment adherence in schizophrenia (125 of 196) compared 
to major depression (96 of 177) shown in Table 3: Flow of 
participants and cumulative rehospitalisation rates at 2-year 
follow-up in both studies [37–38].
For a long time, investigating and comparing patients with 
schizophrenia and major depression was considered useless 
as it was like “comparing apples with peaches”. However, 
despite this critique and encouraged by recent therapeutic 
trends in psychoeducation [49−50] and meta-cognitive train-
ing [51−53] as well as the results of our working group 
on schizophrenia and major depression presented at the 6th 
Kraepelin Symposium last year [54], we analysed the data 
of two randomised studies on this topic. A Consensus Cog-
nitive Battery of cognitive deficits (MATRICS) were set up 
including speed of processing, attention/vigilance, working 
memory, verbal and visual learning as well as reasoning and 



















































































































































































































































































































































































































63 Table 3  Flow of participants and cumulative rehospitalisation rates at 
2-year follow-up in both studies
COP coping-oriented treatment, SUP supportive treatment, PCBT-G 
cognitive-behavioral group therapy for inpatients, PCBT-G + I cogni-
tive behavioral group for inpatients and individual therapy for outpa-
tients, E-CM extended clinical management for inpatients




Randomised: 198 Randomized: 177
Conditions
COP SUP E-CM PCBT-G PCBT-G + I
Pre-treatment
n = 100 n = 96 n = 58 n = 59 n = 60
Analysed at 1-year follow-up
n = 66 n = 64 n = 27 n = 23 n = 20
Analysed at 2-year follow-up
n = 70 n = 55 n = 31 n = 30 n = 25
Rehospitalisation rates
38% 37% 40%* 27%* 34%
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in treatment models based on current research to improve 
cognition in schizophrenia. Aerobic exercise and cognitive 
training may have synergistic effects on learning and overall 
cognitive functioning that can enhance the impact of cogni-
tive training alone [56−57].
The results of our studies are in line with other psychoe-
ducational and cognitive-behavioral interventions in con-
trolled studies in schizophrenia and in major depression. The 
large number of patients and the fact that all groups in both 
studies were comparable regarding clinical and demographic 
data including chlorpromazine equivalents as well as treat-
ment time involved in therapy are the strengths of the study. 
There was a moderate drop-out rate that is comparable with 
other studies.
Limitations of these studies are that we did not biologi-
cally analyze the level of medication to indicate treatment 
adherence. All treatment groups were established in the 
same setting and thus, we could not control interactions 
between patients and we could not guarantee the blindness 
of the raters throughout the studies. The number of hospi-
talizations refers to a vague construct as it might also be 
dependent on the social situation or illness management and 
less on psychopathological criteria. A higher rate in psycho-
pathological assessments could have optimized both studies.
During the last 20 years, illness management programs 
covering primary, secondary and tertiary prevention gained 
importance in psychiatry. Important goals are to prevent the 
onset of the illness, its reoccurrence of symptoms and to 
improve quality of life by reducing disability and limiting or 
delaying recurrence in those already affected by a disease. 
There is a need to develop a concept of the self not exclu-
sively defined in terms of the illness but based on a concep-
tion of one’s individuality and on the remaining possibilities 
of life [29–30].
What are the beneficial psychotherapeutic factors of COP 
and PCBT-G? We agree with Grawe [58] and colleagues 
who listed training competencies, providing insight and 
interactive processes [59] as well as high structure and trans-
parency. We would also add sharing experiences, having the 
possibility to increase social skills and gaining social buffer 
in coping with the illness and anti-stigma processes. [60] 
Identifying and managing early warning signs of relapse, 
developing efficient coping strategies as well as training 
skills to cope with the stressors are very important in the 
treatment of schizophrenia [37−38, 48–51].
In the last 20 years, there was a great change in psycho-
therapy and we are optimistic to reduce even more preju-
dice in psychiatry in the following years [59, 60]. 43 years 
ago, postpsychotic depression in schizophrenia was seen as 
a relatively neglected area despite the risk of suicide and 
prolonged suffering [61]. Nowadays it looks that this topic 
is still relatively neglected although it seems natural that it 
would occur sometimes [62]. Interest shifted to depression 
mediating cognition impairment in schizophrenia or to the 
possible similarity of depressive and schizophrenia anhedo-
nia. From our point of view, it looks interesting to tackle the 
role of depression in the affective/non-affective psychosis 
dichotomy.
Conclusions
The results of both studies are encouraging because they 
suggest that the effects of a relatively time-limited, inpatient 
COP or PCBT-G were sustained over a 2-year follow-up 
period after patients had been discharged into the commu-
nity, and they support the potential benefits of psychosocial 
treatment during the inpatient phase. The study was con-
ducted in a treatment setting that provided a broad range 
of psychotherapeutic and rehabilitative interventions in 
addition to pharmacological treatment, and therefore, one 
might expect better overall outcomes for participants in 
both groups compared to a treatment setting more narrowly 
focused on pharmacological stabilization and safety.
In summary, we found that both patients with schizophre-
nia and affective disorders improved their symptoms over 
the course of the illness. Both group interventions (COP and 
PCBT-G) led to greater increases in knowledge about mental 
illness. There was an increase of psychosocial functioning 
significantly higher mainly in favour of major depression. 
Global Assessment functioning, knowledge about the illness, 
verbal learning memory test improved more pronounced in 
the depressed patients compared to patients with schizophre-
nia. The benefits of the program on symptoms were sus-
tained over two years following discharge from the hospital. 
There were benefits in group therapy COP and PCBT even 
at 2-year follow-up, however, the effects were more pro-
nounced in patients with major depression.
Research on associations between psychotic symptoms 
and cognitive impairment, differential developmental mech-
anisms across affective and non-affective psychosis, and 
treatment options for cognitive impairment are important 
steps for improving the lives of individuals with psychosis.
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